Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

نویسندگان

  • Tal Hasson
  • Sarah Kolitz
  • Fadi Towfic
  • Daphna Laifenfeld
  • Shlomo Bakshi
  • Olga Beriozkin
  • Maya Shacham-Abramson
  • Bracha Timan
  • Kevin D. Fowler
  • Tal Birnberg
  • Attila Konya
  • Arthur Komlosh
  • David Ladkani
  • Michael R. Hayden
  • Benjamin Zeskind
  • Iris Grossman
چکیده

Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA with differently-manufactured glatiramoid Polimunol (Synthon) in mice yielded hundreds of differentially expressed probesets, including biologically-relevant genes (e.g. Il18, adj p<9e-6) and pathways. In human monocytes, 700+ probesets differed between Polimunol and GA, enriching for 130+ pathways including response to lipopolysaccharide (adj. p<0.006). Key differences were confirmed by qRT-PCR (splenocytes) or proteomics (THP-1). These studies demonstrate the complexity of GA's mechanisms of action, and may help inform therapeutic equivalence assessment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Glatiramer acetate in the treatment of multiple sclerosis

Glatiramer acetate is a synthetic, random copolymer widely used as a first-line agent for the treatment of relapsing-remitting multiple sclerosis (MS). While earlier studies primarily attributed its clinical effect to a shift in the cytokine secretion of CD4+ T helper (T(h)) cells, growing evidence in MS and its animal model, experimental autoimmune encephalomyelitis (EAE), suggests that glatir...

متن کامل

Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis

Therapeutic vaccines are antigen-specific agents that inhibit an unwanted immune response to prevent progression of, or eliminate, existing disease. Unlike prophylactic vaccines, developing therapeutic vaccines poses a significant challenge because they can require multimodal immunomodulatory activity to modulate complex pathogenic disease pathways. This is particularly true in autoimmune disor...

متن کامل

Glatiramer acetate therapy: the plot thickens.

G LATIRAMER ACETATE (COPAXONE; TEVA Pharmaceuticals, North Wales, Pa) is a random polymer of glutamic acid, lysine, alanine, and tyrosine, and is of considerable interest for its ability to reduce the frequency of relapses in relapsing-remitting multiple sclerosis (MS). Several mechanisms have been proposed to explain these findings. Lando et al suggested that inhibition of clinical disease in ...

متن کامل

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis

BACKGROUND Glatiramer acetate (GA, Copaxone) has beneficial effects on the clinical course of relapsing-remitting multiple sclerosis (RRMS). However, the exact molecular mechanisms of GA effects are only partially understood. OBJECTIVE To characterized GA molecular effects in RRMS patients within 3 months of treatment by microarray profiling of peripheral blood mononuclear cells (PBMC). MET...

متن کامل

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen-specific T-cell responses in patients with multiple sclerosis (MS). Glatiramer acetate (Copaxone) functioned as a universal antigen, inducing proliferation, independent of any prior exposure to the polymer, in T-cell lines prepared from MS or healthy subjects. However, fo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of Neuroimmunology

دوره 290  شماره 

صفحات  -

تاریخ انتشار 2016